USpolicy

News

ICER says the prices of new drug launches in the US rose 51% in three years, adding up to $1.5bn in first-year costs to US health systems.

News

Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.

News

Job losses start at federal agencies, including HHS, but initial reports suggest some workers who have been let go are quickly being reinstated.

News

AstraZeneca has become the second pharma group to reach an agreement with the Trump administration on Most Favoured Nation (MFN) drug pricing.

Market Access

Two pharmaceutical giants have paused investment in the UK. More than a setback for British life sciences, it’s a warning sign for the future.

News

The first stage of AstraZeneca's promised $50 billion investment in US facilities is underway as it breaks ground on a facility in Virginia.